Jul 17,2023

Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease

Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced robust lobe-specific changes in white matter volume and myelination in Alzheimer’s Disease (AD) patients following six-months of non-invasive gamma stimulation therapy using the at-home wearable device. New imaging data reported from the Phase 2 OVERTURE trial showed that white matter atrophy and demyelination were statistically significantly reduced in all lobes of the left hemisphere and trended towards reduction in the right hemisphere, in patients on Cognito therapy versus sham therapy, demonstrating that 40Hz sensory stimulation may reduce the neurodegeneration associated with AD.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 27,2023

IMAGIO Consortium Receives Innovative Health Initiative EUR 24 Million Grant to Improve Cancer Treatments

Royal Philips announced that the Philips-coordinated IMAGIO consortium of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners, to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 18,2023

An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma

The EMulate Therapeutics Voyager™ is a simple, wearable, home-use device that uses an alternating electromagnetic field to alter biologic signaling within cells. The objective of this study is to assess the safety/feasibility of the Voyager in the treatment of recurrent glioblastoma (rGBM). In this study, patients with rGBM were treated with Voyager as monotherapy or in combination with standard chemotherapy at the Investigator's discretion. Safety was assessed by incidence of adverse events associated with the Voyager. A total of 75 patients were enrolled and treated for at least one day with the Voyager (safety population). Device-related adverse events were uncommon and generally did not result in interruption or withdrawal from treatment. The data support the safety and feasibility of the Voyager for the treatment of rGBM. Further prospective study of the device is warranted.

CLINICAL STUDY

#connected device

#dtx

View Analyst & Ambassador Comments
Go to original news
Jul 10,2023

AI Tool Decodes Brain Cancer's Genome During Surgery

Harvard Medical School researchers have developed an AI tool called CHARM (Cryosection Histopathology Assessment and Review Machine) that can rapidly decode a brain tumor's DNA during surgery. The tool helps neurosurgeons make real-time decisions about the amount of brain tissue to remove and the potential for targeted treatments. The AI tool achieved high accuracy in classifying different molecular mutations and glioma subtypes, providing valuable information for treatment planning. Further validation and regulatory clearance are required before clinical deployment.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 12,2023

Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study

Tempus announces the GEMINI study, aiming to create a comprehensive dataset for non-small cell lung cancer (NSCLC) patients. The study focuses on early and late-stage NSCLC patients, utilizing Tempus' molecular profiling portfolio and AI-powered platform to analyze tumor biology, disease progression, and therapy efficacy. The results will contribute to biomarker discovery and precision medicine advancements. Tempus is a technology company utilizing AI in healthcare for precision medicine solutions and therapeutic development.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 19,2023

Trial of VR therapy for myopia in kids starts in UK

German digital health company Dopavision has teamed up with clinical trials start-up Lindus Health on the 12-month study, which will involve more than 20 youngsters aged between six and 12 with a refractive error between –0.75 and –5.00 diopters, ranging from mild to severe short-sightedness. the new study is testing the effects of MyopiaX, a smartphone app that stimulates dopamine release in the retina of children while they play games using a VR headset. MyopiaX is the first of Dopavision’s digital therapeutics to start clinical testing, and chief executive Mark Wuttke said it was an “important milestone” for the company as it will provide “the first clinical insights into our unique therapeutic approach to manage myopia.”

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 18,2023

An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma

The EMulate Therapeutics Voyager™ is a simple, wearable, home-use device that uses an alternating electromagnetic field to alter biologic signaling within cells. The objective of this study is to assess the safety/feasibility of the Voyager in the treatment of recurrent glioblastoma (rGBM). In this study, patients with rGBM were treated with Voyager as monotherapy or in combination with standard chemotherapy at the Investigator's discretion. Safety was assessed by incidence of adverse events associated with the Voyager. A total of 75 patients were enrolled and treated for at least one day with the Voyager (safety population). Device-related adverse events were uncommon and generally did not result in interruption or withdrawal from treatment. The data support the safety and feasibility of the Voyager for the treatment of rGBM. Further prospective study of the device is warranted.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 18,2023

Neurolief Announces Positive Results from the MOOD Trial Interim Analysis: Brain Neuromodulation Therapy for Major Depressive Disorder

Neurolief's MOOD pivotal trial for Relivion®DP, a neuromodulation therapy for Major Depressive Disorder (MDD), yielded positive results in an interim analysis. The study will continue as planned, and full results will be submitted to the FDA and CE after completion.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 14,2023

Lark Health’s AI Coaching Drives Weight Loss Results in HPSAs

Lark Health conducted studies on their digital coaching programs, highlighting the positive outcomes in diabetes prevention. Their digital diabetes prevention program (DPP) reduced the risk of type 2 diabetes and promoted weight loss in underserved areas. Additionally, the program showed a decrease in depressive symptoms and improved engagement with the use of self-monitoring technologies.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 30,2023

Vida Health’s integrated cardiometabolic and mental health solution achieves meaningful sustained clinical outcomes

Vida Health's integrated digital health diabetes management program showed significant and sustained improvements in glycemic control and depressive symptoms among participants, according to a study published in the Journal of Medical Internet Research. The study, Improvements in Glycemic Control and Depressive Symptoms among adults with Type 2 Diabetes: A Retrospective Study, drew from a sample of 1,128 participants with diabetes enrolled in Vida’s integrative digital health diabetes management program. This program is designed to enable members to manage both their physical as well as mental health. The results show an average -1.4 point reduction in HbA1C at 4 months that was sustained at 1 year for those with a baseline HbA1C of >=8 and participants who saw improvements in depression acuity had almost 2x greater improvements in HbA1c.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY